These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 21545648

  • 1. Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.
    Dailly E, Rodallec A, Allavena C, Deslandes G, Garnier E, Billaud E, Ferré V, Reliquet V, Bouquié R, Raffi F, Jolliet P.
    Fundam Clin Pharmacol; 2012 Aug; 26(4):538-42. PubMed ID: 21545648
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
    Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D, ANRS Co3 Aquitaine Cohort.
    Antivir Ther; 2008 Aug; 13(2):271-9. PubMed ID: 18505178
    [Abstract] [Full Text] [Related]

  • 4. Resistance profile of darunavir: combined 24-week results from the POWER trials.
    de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, Picchio G, Lefebvre E, de Béthune MP.
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):379-88. PubMed ID: 18327986
    [Abstract] [Full Text] [Related]

  • 5. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D, ANRS Resistance Study Group.
    J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
    Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, González-Lahoz J, Soriano V.
    J Antimicrob Chemother; 2007 Oct; 60(4):885-8. PubMed ID: 17646201
    [Abstract] [Full Text] [Related]

  • 7. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [Abstract] [Full Text] [Related]

  • 8. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
    Delaugerre C, Mathez D, Peytavin G, Berthé H, Long K, Galperine T, de Truchis P.
    AIDS; 2007 May 31; 21(9):1210-3. PubMed ID: 17502734
    [Abstract] [Full Text] [Related]

  • 9. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G.
    J Clin Virol; 2006 Apr 31; 35(4):414-9. PubMed ID: 16280255
    [Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
    Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G.
    J Antimicrob Chemother; 2011 Jan 31; 66(1):192-200. PubMed ID: 21037251
    [Abstract] [Full Text] [Related]

  • 11. [Resistance to darunavir].
    García Deltoro M.
    Enferm Infecc Microbiol Clin; 2008 Oct 31; 26 Suppl 10():51-60. PubMed ID: 19195460
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, Voujon D, Bossi P, Ktorza N, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V.
    J Med Virol; 2004 Sep 31; 74(1):16-20. PubMed ID: 15258963
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
    Delaugerre C, Pavie J, Palmer P, Ghosn J, Blanche S, Roudiere L, Dominguez S, Mortier E, Molina JM, de Truchis P.
    AIDS; 2008 Sep 12; 22(14):1809-13. PubMed ID: 18690163
    [Abstract] [Full Text] [Related]

  • 19. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A, Marcelin AG, Calvez V.
    HIV Med; 2009 Nov 12; 10(10):620-6. PubMed ID: 19601995
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.